linjc16/ctgov huggingface dataset:
Dual-Plane Breast Augmentation: Axillary Approach With Assistant of Endoscope

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the feasibility and outcome of performing dual plane breast augmentation with assistant of endoscope by axillary approach.

Detailed Description
-----------------
Dual plane augmentation mammoplasty is a logical approach to realize the benefits of retromammary and partial retropectoral implant placement while minimizing the tradeoffs of other pocket locations. Traditionally, dual plane augmentation has been performed using transareolar or inframammary fold approach. However, the approach is unacceptable to Chinese patients because of the front scar formation. For aesthetic reasons, the axillary incision is more acceptable approach for augmentation mammoplasty. The endoscope assistant technique has been widely used in transaxillary breast augmentation. It provides the feasibility to perform dual plane breast augmentation by axillary approach. In this research, at least 40 patients with light degree of glandular ptotic and constricted lower pole breasts are selected to receive soft cohesive gel microtextured anatomic style silicone implants. Portions of the pectoralis major muscle is split without its release from the costal margin with the help of a 10mm, 30°endoscope and endoscopic diathermy scissors through a 4-cm incision in the axilla each side. Bleeding during surgery is kept to the minimum. The results of outcomes, operative time, bleeding volume, drainage volume, complications are observed.

Conditions
-----------------
Mammoplasty

Intervention / Treatment
-----------------
* Procedure: Transaxillary dual plane technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women who want breast augmentation using the implants.Especially for the patients with glandular ptotic (< I degree) breasts thick soft tissues (> 10 mm) in the low pole of the breast Exclusion Criteria: With thin soft tissues (< 9 mm) in the low pole of the breast

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Transaxillary dual plane technique|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 98% of the patient satisfied with softer, more natural breasts. The procedure provided more accurate bleeding control, faster postoperative coverage. |  | within half year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
augmentation mammoplasty, Dual plane, Endoscope, Transaxillary incision
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

Study Overview
=================
Brief Summary
-----------------
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.

Official Title
-----------------
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Anti-HIV Immune Serum Globulin (Human)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Proof of HIV infection. Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other anti-HIV therapy. OR a diagnosis of AIDS and = or > 3 months of AZT therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: HIV-induced neurological disease. IgA negative. Concurrent Medication: Excluded: Immunomodulating agents. Steroids. Interferons. Patients with the following are excluded: Active substance abuse. Use of immunomodulating drugs such as steroids or interferons. HIV-induced neurological disease. IgA negative. Required with a diagnosis of AIDS: = or > 3 months of zidovudine (AZT) therapy. Active substance abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Anti-HIV Immune Serum Globulin (Human)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Immunization, Passive
Preoperative Nutritional Support in Esophagectomy or Pancreaticoduodenectomy

Study Overview
=================
Brief Summary
-----------------
We are proposing to evaluate the benefit of preoperative nutritional support with Impact Advanced Recovery in the most vulnerable group of elective gastrointestinal surgery patients who may experience a complication, esophagus and pancreas resections, and hypothesize that oral supplementation with 3 servings (0.75 L) Impact Advanced Recovery will reduce postoperative stay by 10-20% and reduce the incidence of major complications by 25%.

Official Title
-----------------
Preoperative Nutritional Support Reduces Postoperative Stay and Incidence of Complications in Patients Undergoing an Esophagectomy or Pancreaticoduodenectomy

Conditions
-----------------
Esophagectomy, Pancreaticoduodenectomy

Intervention / Treatment
-----------------
* Dietary Supplement: Impact Advanced Recovery
* Dietary Supplement: No supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female age 18 years or older of any race-ethnicity who will undergo an elective esophagectomy or pancreaticoduodenectomy. Surgery will be scheduled 5-7 days after consent date - Exclusion Criteria: Surgery is urgent or emergent and/or patient would be unable to consume nutritional supplement for 5-7 days Patient is currently receiving enteral (tube) or parenteral (IV) nutritional support Patients with known pre-existing renal failure requiring a low protein diet Patient is unable to drink 3 servings/day of a liquid supplement -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team. | Dietary Supplement: Impact Advanced Recovery<br>* Nutritional supplement<br>|
| Placebo Comparator: 2<br>Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team. | Dietary Supplement: No supplement<br>* No supplement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative stay in days |  | Postoperative stay in hospital & 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of major complications |  | Postoperative stay in hospital & 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Esophagectomy, Pancreaticoduodenectomy, Whipple
Screening for Obstructive Sleep Apnea in Medical Patients

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea (OSA) is highly prevalent in the general population and is associated with multiple adverse cardiovascular consequences. Screening for OSA is recommended in those with typical symptoms, such as daytime sleepiness, loud snoring, or abrupt awakenings with gasping or choking. Patients admitted to the general medical wards with these symptoms will be evaluated for the possibility of having OSA.

Detailed Description
-----------------
Obstructive sleep apnea (OSA) is a disease that is highly prevalent in all communities and is associated with adverse cardiovascular events. Screening for OSA is recommended in men and women who have the typical symptoms, including snoring, daytime sleepiness, or abrupt awakenings with choking or gasping. OSA screening is also recommended for those with resistant hypertension, bradyarrhythmias, and atrial fibrillation. Heart failure patients should also be screened for OSA. It is very important to increase the use of OSA screening especially in patients admitted to the medical floor in tertiary care hospitals. No study has evaluated this topic in the Middle East in the past.

Official Title
-----------------
Screening for Obstructive Sleep Apnea in the General Medical Ward in Tertiary Care Centers in the Middle East

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Other: Screening for obstructive sleep apnea


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to sign an informed consent Patient is admitted to the medical ward in a tertiary hospital Exclusion Criteria: Patients known to have obstructive sleep apnea. Patients younger than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Screening for obstructive sleep apnea|Patient will be interviewed and asked of there are symptoms of snoring, day somnolence, chocking or gasping during sleep|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants who are found to have obstructive sleep apnea | Those who are found to have symptoms of OSA will be referred for further evaluation to get the final diagnosis of OSA | From date of study enrollment until the date of first documented diagnosis of obstructive sleep apnea, assessed up to 4 weeks. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive sleep apnea, Symptomatology, Middle East
Cardiogenic Acute Pulmonary Edema in Subjects Over 75 Years Old: Impact of Non-invasive Ventilation on Mortality

Study Overview
=================
Brief Summary
-----------------
People aged over 75 represent almost 10% of the general population, and 12 to 14% of patients consulting emergency departments. Cardiogenic acute pulmonary edema (APO) is a very common reason for admission to the emergency room. The effectiveness of non-invasive ventilation (NIV) has been demonstrated during the management of PAO and would allow, compared to medical treatment alone, a more rapid improvement in clinical and gasometric parameters as well as a reduction in the need for ventilation. orotracheal intubation. On the other hand, the impact of NIV on mortality in cardiogenic PAO seems poorly defined, with lower levels of scientific evidence regarding a possible benefit in terms of survival, particularly in the elderly population. The objective of this study is to determine whether the use of NIV in cardiogenic PAO in elderly subjects admitted to the emergency room of Strasbourg University Hospital would have an impact in terms of mortality up to 6 months compared to medical treatment alone.

Official Title
-----------------
Cardiogenic Acute Pulmonary Edema in Subjects Over 75 Years Old: Impact of Non-invasive Ventilation on Mortality

Conditions
-----------------
Cardiogenic Pulmonary Edema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult subject (> 75 years old) Admission to the NHC emergency room between January 1, 2021 and October 31, 2021 Diagnosis of cardiogenic PAO Indication of NIV according to current recommendations Subject not opposing the reuse of their data for scientific research purposes. Exclusion Criteria: Subject having expressed his opposition to the reuse of his data for scientific research purposes. Presence of an absolute contraindication to NIV Respiratory distress due to pneumonia or other diagnosis RT-PCR Sars Cov 2 positive in emergency

Ages Eligible for Study
-----------------
Minimum Age: 76 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival Analysis |  | 6 months after cardiogenic acute pulmonary edema | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiogenic Pulmonary Edema, Acute pulmonary edema, Non-invasive ventilation
Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to analyze a population with symptoms associated with adverse reactions to foodstuffs (ARFS). To determine the levels of food-specific immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) antibody reactions (AbR).

Detailed Description
-----------------
Volunteers with symptoms related with adverse reactions to foodstuffs (ARFS) and suspicion of having a food allergy or a food intolerance are enrolled in this study. A 50μl of capillary whole blood is analyzed and the levels of food-specific immunoglobulin G4 (IgG4) or immunoglobulin E (IgE) antibody reactions (AbR) are determined.

Official Title
-----------------
Food-specific Immunoglobulin G4 and Immunoglobulin E Antibody Reactions in a Population With Adverse Reactions to Foodstuffs-related Symptoms

Conditions
-----------------
Immunoglobulin E-Mediated Food Allergy, Immunoglobulin G4-Related Disease, Symptoms and Signs, Adverse Reaction to Food

Intervention / Treatment
-----------------
* Diagnostic Test: Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (>18 years of age) To present symptoms related to adverse reactions to foodstuffs (ARFS) Exclusion Criteria: Antibiotic treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food-specific Immunoglobulin G4 antibody reactions | Immunoassay kits (NutriSMART® In-Vitro Diagnostic kit, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms. | 0 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food-specific Immunoglobulin E antibody reactions | Immunoassay kits (Fastcheckpoc20® In-Vitro Diagnostic kit, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms. | 0 days |